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Abstract
Background: The definition of “clinical asthma remission” is based on absence of symptoms and use of
medication. However, in the majority of these subjects airway inflammation is still present when measured. In the
present study we investigated whether “complete asthma remission”, additionally defined by the absence of
bronchial hyperresponsiveness (BHR) and the presence of a normal lung function, is associated with the absence of
airway inflammation.
Methods: Patients with a former diagnosis of asthma and a positive histamine provocation test were re-examined
to identify subjects with complete asthma remission (no asthma symptoms or medication, PC20 histamine > 32
mg/ml, FEV1 > 90% predicted). Patients with PC20 histamine ≤ 32 mg/ml were defined as current asthmatics and
were divided in two groups, i.e. asthmatics with and without BHR to adenosine 5’monophoshate (AMP). Sputum
induction was performed 1 week before and 1 hour after AMP provocation. Sputum induction and AMP
provocation were previously shown to be sensitive markers of airway inflammation.
Results: Seven patients met criteria for complete asthma remission. Twenty-three were current asthmatics,
including twelve without hyperresponsiveness to AMP. Subjects with complete asthma remission showed no AMP-
induced sputum eosinophilia (median (range) 0.2 (0 - 4.6)% at baseline and 0.2 (0 - 2.6)% after AMP). After AMP,
current asthmatics had a significant increase in sputum eosinophils (0.5 (0 - 26.0)% at baseline and 2.6 (0 - 32.0) %
after AMP), as had the subgroup of current asthmatics without hyperresponsiveness to AMP (0.2 (0 - 1.8)% at
baseline and 1.3 (0 - 6.3)% after AMP).
Conclusions: Subjects with complete asthma remission, in contrast to subjects with current asthma, do not
respond with eosinophilic inflammation in sputum after AMP provocations. These data lend support to the
usefulness of the definition of complete asthma remission.
Background
Asthma symptoms may diminish over time in a subgroup
of patients and sometimes even disappear completely.
The loss of asthma symptoms in the absence of need for
pulmonary medication has been defined as “clinical or
symptomatic asthma remission”[1-4]. However, the
majority of patients with clinical or symptomatic remis-
sion still shows bronchial hyperresponsiveness (BHR)
[1-4], suggesting that the disease asthma is not yet cured.
This is supported by the observation that the broncho
alveolar lavage (BAL) fluid contains increased levels of
eosinophils in some asthmatic children with clinical
asthma remission, when compared to healthy controls
[5]. Furthermore, higher numbers of eosinophils, T cells,
mast cells and expression of IL-5 were found in the air-
way mucosa of patients with clinical remission than in
healthy controls[6].
Given the persistent presence of airway inflammation
and BHR despite the asymptomatic status, it is likely
that a more strict definition is required to signify
whether an individual really is “cured” from asthma and
can be regarded to have complete remission. The defini-
tion of clinical asthma remission has therefore pre-
viously been extended to “c o m p l e t ea s t h m ar e m i s s i o n ”,
also including absence of BHR and normal lung func-
tion (FEV1>90%predicted) [1,4]. A 25-year follow up
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all diagnosed with a positive bronchial hyperresponsive-
ness test to histamine and clinical asthma symptoms
according to ATS criteria, showed a prevalence of clini-
cal remission and complete remission of 40% and 11%
respectively by the age of 38-69 years[1]. In another fol-
low up study, 119 allergic asthmatic children were
retested after 30 years and 52% were in clinical remis-
sion and 22% in complete asthma remission[4]. To our
knowledge, it has not been investigated so far whether
asthmatic airway inflammation is objectively absent in
this subgroup of subjects with complete asthma
remission.
We have previously shown that adenosine 5’monopho-
sphate (AMP) provocation induces sputum eosinophilia
in asthma patients with and without inhaled steroid use
[7]. We considered this as an interesting tool to investi-
gate airway inflammation, because the recruitment pro-
cess of eosinophils after an AMP challenge indicates the
presence of an active inflammatory response.
The present study was set up to investigate whether
such an inflammatory response indeed is absent and
cannot be induced in subjects with complete asthma
remission. To this aim we compared inflammatory
cells 1 week before and 1 hour after AMP provocation
in induced sputum from subjects with complete remis-
sion and from patients with current asthma. Since not
all asthmatics are responsive to AMP, we divided these
subjects in an AMP responsive and a non-responsive
group. These subgroups enabled us to additionally
study the dose-response effect op AMP on sputum
eosinophil numbers.
Methods
Subjects
Non-smoking asthma patients aged between 18 and 70
years, without oral or inhaled corticosteroids were
recruited. All patients originated from research cohorts
investigated earlier by our research group and all had a
doctor’s diagnosis of asthma and a documented PC20
histamine ≤ 32 mg/ml in the past[4,8-10]. All patients
had to be able to expectorate sputum after inhalation of
hypertonic saline. In order to compare the effects of the
highest cumulative dose of AMP (639.99 mg) on the
influx of inflammatory cells in induced sputum, current
asthma patients were divided in those with a negative
and a positive AMP provocation test. Current asthma in
these patients was proven by a positive bronchial hyper-
responsiveness test to histamine. Patients were consid-
ered to have no asthma symptoms when they answered
negatively on questions regarding cough and sputum in
wintertime, dyspnea, wheeze and asthma attacks in the
last three years. The study protocol was approved by the
local medical ethics committee; all participants gave
their written informed consent.
Patients were assigned to 3 different groups according
to the following criteria:
￿ Complete asthma remission: former diagnosis of
asthma, PC20 A M P>3 2 0m g / m la n dP C 20 histamine >
32 mg/ml, FEV1 % predicted > 90%, no asthma symp-
toms, no asthma medication.
￿ C u r r e n ta s t h m aw i t han e g a t i v eP C 20 AMP:f o r m e r
diagnosis of asthma, PC20 AMP > 320 mg/ml, PC20 his-
tamine ≤ 32 mg/ml.
￿ C u r r e n ta s t h m aw i t hap o s i t i v eP C 20 AMP:f o r m e r
diagnosis of asthma, PC20 AMP ≤ 320 mg/ml.
Study Design
Patients visited the hospital twice. At the first visit lung
function, blood collection and sputum induction were
obtained. The second visit followed after 1-2 weeks and
included AMP provocation test and sputum induction 1
hour after the final dose of AMP. In patients with a nega-
tive AMP provocation (dose AMP > 320 mg/ml) bron-
chial hyperresponsiveness to histamine was measured > 1
week later. To facilitate comparison with historical data
on bronchial hyperresponsiveness to histamine, the maxi-
mum provocative dose of histamine in the present study
was also set at 32 mg/ml (with 30-seconds tidal breathing
method, a dose that is comparable with 8 mg/ml in the
2-minute tidal breathing method).
Questionnaire
The Dutch version of the British Medical Research
Council’s standard questionnaire was used[11]. Patients
were considered asymptomatic if they answered nega-
tively on questions regarding cough, sputum, dyspnea,
wheeze and asthma attacks
Lung Function
FEV1 was measured with a calibrated water-sealed spi-
rometer according to standardized guidelines[12,13].
Reversibility of the FEV1%predicted was measured after
administration of 400 μg of salbutamol. Provocation
tests were performed with a method adapted from
Cockcroft and coworkers[14,15]. After 2-min tidal
breathing and an initial nebulized saline challenge, sub-
jects inhaled doubling concentrations AMP (0.04 to 320
mg/ml) at 5-min intervals. Bronchial hyperresponsive-
ness to histamine was tested as reported previously[8],
using 30-seconds tidal breathing and doubling concen-
trations ranging from 0.13 to 32 mg/ml.
Sputum Induction and Sputum Processing
Sputum was induced by inhalation of hypertonic saline
aerosols as previously described[13]. Hypertonic saline
Volbeda et al. Respiratory Research 2010, 11:106
http://respiratory-research.com/content/11/1/106
Page 2 of 7(5%) was nebulized over 3 consecutive periods of 5
min. Whole sputum samples were processed according
to the method of Fahy and colleagues with some modi-
fications[13,16]. Sputum cell cytospins were stained
with May Grünwald Giemsa (MGG) and cell differen-
tials from in total 600 viable, non squamous cells were
assessed in a blinded fashion. Sputum was not scored
if the percentage of squamous cells was > 80 percent
or the total number of non-squamous cells was < 600.
Number of sputum drop-outs because of 80% squa-
mous cells were 6 at baseline and 0 after AMP, drop
outs because of < 600 non-squamous cells were 2 at
baseline and 4 after AMP. Additionally, no sputum
could be induced in 8 patients at baseline and 6 after
AMP.
Histamine ELISA
A histamine ELISA was purchased from IBL (Hamburg,
Germany) for quantitative detection of histamine in spu-
tum supernatant. All reagents were provided in the kit.
The protocol was as follows: the acetylated samples,
controls and standards are pipetted into a 96-wells
plate. After adding enzyme conjugate and histamine
antiserum the plate was incubated for 3 hours on an
orbital shaker. After washing TMB substrate solution
was added to each well and incubated for 20 minutes.
The substrate reaction was stopped and the optical den-
sity was measured at 450 nM.
Allergic Parameters
The concentration of eosinophilic cationic protein (ECP)
in sputum was measured using a fluoroenzyme immu-
noassay (ImmunoCAP ECP, Pharmacia, Uppsala, Swe-
den). Total serum IgE (IU/L) was measured by a solid-
phase immunoassay (VIDAS total IgE kit, BioMérieux,
Marcy l’Etoile, France). The Phadiatop screening test
was performed on the ImmunoCap system according to
the instructions of the manufacturer (Phadia AB, Swe-
den). Results were presented as quotients (fluorescence
of the serum of interest divided by the fluorescence of a
control serum). Positive Phadiatop was defined as
patient serum/control serum >1.
Statistics
All analyses were performed using SPSS (version 16.0;
SPSS Inc, Chicago, IL, USA). Non-parametric tests were
used for analysis. Wilcoxon signed rank test was used
for paired testing within groups between measurements
at baseline and after AMP provocation. Mann-Whitney
U test was used for testing differences between groups.
Two tailed p-values of < 0.05 were considered statisti-
cally significant.
Results
Patient Characteristics
47 patients were enrolled in the study. 17 patients were
excluded from analysis because they were not able to
produce sputum both before and after AMP provocation
or because the quality of sputum was too low to allow
analysis. 3 of the excluded subjects had complete asthma
remission and 14 current asthma. The included and
excluded groups did not differ statistically regarding age,
sex, FEV1 %pred, reversibility of FEV1, allergy and blood
eosinophils. From the included patients, 7 patients met
the inclusion criteria for complete asthma remission and
were compared with 23 current asthma patients. Of
these current asthmatics 11 had a positive PC20AMP
(PC20 AMP ≤ 320 mg/ml) and 12 had a negative
PC20AMP (PC20 AMP > 320 mg/ml, but a PC20 Hista-
mine ≤ 32 mg/ml) (table 1). FEV1 % predicted in sub-
jects with complete asthma remission was significantly
higher than in patients with current asthma. Atopy was
most frequent in asthmatics with a positive PC20AMP,
significantly more frequent than in current asthmatics
w i t han e g a t i v eP C 20AMP and subjects in complete
asthma remission
Sputum Data
Complete Asthma Remission versus Current Asthma
At baseline, total sputum cell count, macrophage, neu-
trophil, lymphocyte and eosinophil differential counts
were similar in all investigated groups (table 2). After
AMP provocation, sputum eosinophils did not increase
in subjects with complete asthma remission in contrast
to patients with current asthma, resulting in a signifi-
cantly higher percentage eosinophils post AMP chal-
lenge in the current asthma groups (figure 1). Similar
trends were observed for sputum ECP, i.e. median
(range) levels before and after AMP were 16.0 (2.5 -
170.0) and 14.8 (2.6 - 63.7), respectively, in the group
with complete asthma remission and 36.3 (6.0 - 2467.0)
and 47.3 (9.0 - 1628.0) in the group with current
asthma. Histamine levels in sputum supernatant were
comparable in the group with complete asthma remis-
sion and with current asthma. Median (range) levels
before and after AMP provocation were 13.4 (2.8 - 29.8)
ng/ml and 12.4 (4.0 - 137.0) ng/ml, respectively, in the
group with complete asthma remission, and 9.8 (0.2 -
38.0) ng/ml and 8.4 (3.0 - 30.5) ng/ml in the group with
current asthma.
AMP provocation had little effect on the other inflam-
matory cells. Analysis with absolute sputum cell num-
bers showed comparable results with sputum cell
percentages, however data are not presented because of
differences in total cell numbers between groups.
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Complete remission Current asthma
(n = 7) Total group
(n = 23)
Negative
PC20 AMP
(n = 12)
Positive
PC20 AMP
(n = 11)
Sex (M/F) 2/5 14/9 6/6 8/3
Age (years) 53.0 (32 - 67) 48.0 (35 - 70) 47.5 (35 - 70) 48.0 (38 - 62)
FEV1 (% predicted) 108.0 (102 - 144)*,
‡‡ 97 (76 - 131) 96.2 (76.2 - 123) 96.5 (84.8 - 131)
PC20 AMP (mg/ml) >320 >320 (0.02 - >320) >320 12.0 (0.02 - 174)
Cumulative AMP dose (mg) 639.99 639.99 (0.02 - 639.99) 639.99 39.99 (0.02 - 639.99)
PC20 Histamine (mg/ml) >32.0 N.A. 16.9 (2.5 - 32.0) N.A.
Reversibility FEV1 (%) 4.59 (1.76 - 9.72) 5.42 (-2.98 - 26.7) 3.15 (-2.98 - 12.2)
‡ 9.40 (1.76 - 26.7)
IgE (IU/L) 47 (7 - 166) 66 (11 - 558) 61 (14 - 246) 78 (11 - 558)
Positive Phadiatop (n (%)) 3 (43)
‡ 15 (65) 5 (42)
‡ 10 (91)
Eosinophils blood (× 10
9/L) 0.12 (0.09 - 0.24) 0.15 (0.03 - 0.35) 0.11 (0.03 - 0.35) 0.17 (0.07 - 0.25)
Values are medians (ranges), unless stated otherwise.
Definition of abbreviations:P C 20 AMP = provocative concentration of adenosine 5’monophoshate causing a 20% fall in FEV1; reversibility FEV1 = change in FEV1,
expressed as increase in percentage predicted normal value after 400 μg of Salbutamol; Positive Phadiatop = specific IgE’s in patient serum/control serum >1;
n = number; N.A. = not available.
*p≤ 0.05 versus current asthma total group.
‡ p ≤ 0.05,
‡‡ p ≤ 0.01 versus current asthma PC20 AMP positive.
Table 2 Sputum before and after amp Provocation
Complete remission Current asthma
(n = 7) Total group
(n = 23)
Negative
PC20 AMP
(n = 12)
Positive
PC20 AMP
(n = 11)
Total cells (×10
6/ml)
Baseline 0.6 (0.1 - 2.9) 0.3 (0.1 - 2.3) 0.4 (0.1 - 2.3) 0.3 (0.2 - 2.1)
After AMP 0.2 (0.1 - 1.4)
θ 0.3 (0.1 - 3.0) 0.4 (0.2 - 3.0) 0.3 (0.1 - 0.8)
Change -0.5 (-1.5 - 0.0) 0.0 (-1.7 - 1.5) 0.1 (-1.1 - 1.5) 0.0 (-1.7 - 0.2)
Squamous cells (%)
Baseline 23.8 (5.3 - 67.0) 21.3 (0.8 - 70.3) 19.2 (0.8 - 70.3) 21.3 (4.7 - 43.3)
After AMP 41.5 (9.0 - 49.0) 17.5 (0.5 - 64.5) 19.9 (0.5 - 64.5) 17.5 (1.7 - 24.5)
Change 14.0 (-26.2 - 22.2) -2.0 (-25.8 - 27.0) -1.1 (-16.5 - 27.0) -2.0 (-25.8 - 10.6)
Neutrophils (%)
At baseline 62.2 (18.9 - 77.6) 55.2 (19.8 - 94.5) 56.8 (20.7 - 94.5) 55.2 (19.8 - 93.6)
After AMP 48.1 (15.0 - 90.4) 59.0 (22.3 - 96.8) 71.3 (25.7 - 96.8) 52.7 (22.3 - 71.0)
Change -3.9 (-37.9 - 58.1) -3.2 (-35.1 - 68.0) -0.4 (-29.5 - 68.0) -5.1 (-35.1 - 25.4)
Macrophages (%)
At baseline 35.8 (19.9 - 77.7) 32.7 (5.3 - 76.4) 40.0 (5.3 - 76.4) 32.7 (5.6 - 76.2)
After AMP 49.1 (8.9 - 84.2) 29.2 (3.0 - 72.5) 23.1 (3.0 - 72.5) 39.1 (12.6 - 61.2)
Change 11.2 (-56.7 - 41.3) 1.2 (-65.1 - 28.6) 0.0 (-65.1 - 28.6) 1.2 (-37.1 - 20.6)
Eosinophils (%)
At baseline 0.2 (0.0 - 4.6) 0.5 (0.0 - 25.7) 0.2 (0.0 - 1.8)
‡‡ 1.9 (0.0 - 25.7)
After AMP 0.2 (0.0- 2.6)*
, ‡‡‡ 2.6 (0.0 - 32.0)
θθθ 1.3 (0.0 - 6.3)
‡‡‡, θ 5.9 (2.5 - 32.0)
θθ
Change -0.2 (-2.3 - 0.2)**
, ‡‡,§ § 1.4 (-2.3 - 13.7) 0.7 (-0.5 - 6.1)
‡ 2.7 (-2.3 - 13.7)
Lymphocytes (%)
At baseline 2.2 (1.4 - 7.3) 1.9 (0.0 - 6.9) 2.0 (0.2 - 6.9) 1.9 (0.0 - 5.9)
After AMP 0.3 (0.0 - 2.5)*
, ‡‡, θ,§ 1.3 (0.0 - 6.1) 0.8 (0.0 - 6.1) 1.7 (0.7 - 4.8)
Change -1.8 (-7.0 - 0.7) -0.2 (-4.9 - 4.8) -0.4 (-4.2 - 3.8) 0.1 (-4.9 - 4.8)
Squamous cells were not included in the number of total cells and in the percentages of all other cell types.
Values are medians (ranges).
*p≤ 0.05, ** p ≤ 0.01 versus current asthma total group.
‡ p ≤ 0.05,
‡‡ p ≤ 0.01,
‡‡‡ p ≤ 0.001 versus current asthma PC20 AMP positive.
§ p ≤ 0.05,
§§ p ≤ 0.01 versus current asthma PC20 AMP negative.
θ p ≤ 0.05,
θθp ≤ 0.01,
θθθp = 0.001 versus at baseline.
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Current Asthma
Allergy was more frequently present in current asth-
matics with a positive than with a negative AMP provo-
cation test (table 1). Sputum eosinophils increased
significantly after AMP provocation in current asthma
patients, even in those without AMP responsiveness (fig-
u r e1 ) .H o w e v e r ,t h ei n c r e a s ei ns p u t u me o s i n o p h i l s
after AMP provocation was significantly higher in AMP
positive subjects (table 2). Also higher ECP levels were
observed in AMP positive current asthma patients, i.e.
median levels before and after AMP were 41.6 (11.9 -
262.0) μg/l and 62.2 (15.2 - 467.0) μg/l, respectively,
compared to 32.3 (6.0 - 2467.0) μg/l and 37.8 (9.0 -
1628.0) μg/l in AMP negative current asthma patients.
Histamine levels in sputum supernatant were compar-
able in AMP positive and AMP negative subjects with
current asthma. Median (range) levels before and after
AMP were 11.0 (4.8 - 38.0) ng/ml and 9.1 (4.9 - 28.0)
ng/ml, respectively, in the AMP positive group, and 9.5
(0.2 - 28.8) ng/ml and 8.3 (3.0 - 30.5) ng/ml in the AMP
negative group.
Discussion
To our knowledge, this is the first study investigating
sputum inflammation in subjects meeting the criteria
for complete asthma remission. Our definition of com-
plete asthma remission also includes a normal lung
function and absence of bronchial hyperresponsiveness
in addition to the absence of asthma symptoms and
medication, which was previously defined as clinical
asthma remission. Sputum inflammation at baseline and
t h er e s p o n s ea f t e rA M Pp r o v o c a t i o nw a sc o m p a r e d
between subjects with current asthma and complete
asthma remission. Levels of sputum eosinophils at base-
line and blood eosinophils were not significantly differ-
ent between these groups. However, we demonstrate
that AMP provocation increases the number of sputum
eosinophils in current asthmatics, yet not in those with
complete asthma remission. Similar trends were
o b s e r v e df o rE C P .T h i st h u ss u g g e s t st h a tt h el a t t e r
group indeed has outgrown their asthma and eosino-
phils are not in a primed state.
T h ep r e s e n ts t u d ys h o w st h eu s e f u l n e s so fm e a s u r i n g
hyperresponsiveness and FEV1 in recognizing subjects
with complete asthma remission. Several studies have
shown that a clinical definition based on the absence of
asthma symptoms and no use of asthma medication is
insufficient to definitely assess that asthma is cured.
Many of these subjects still show features of persistent
asthma, such as presence of hyperresponsiveness and/or
a low lung function[1-4] or ongoing airway inflamma-
tion[5,6]. The concept of complete asthma remission
has previously been introduced as an alternative to the
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Figure 1 Changes in sputum eosinophil % from baseline to
post-AMP provocation in subjects with complete asthma
remission, current asthma patients with a negative AMP
provocation and current asthma patients with a positive AMP
provocation. Data are presented in a semi-log plot to optimize
visualization of minor and major changes.
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remission is defined by the combined absence of asthma
symptoms, asthma medication, airway obstruction, and
bronchial hyperresponsiveness[1,4]. In the present study,
we investigated the concept of complete asthma remis-
sion in more detail by measuring inflammatory cells in
induced sputum before and after AMP provocation in
subjects meeting the criteria for complete asthma remis-
s i o n .T h ef i n d i n gt h a ts p u t u me o s i n o p h i l sd on o t
increase significantly after AMP provocation in these
subjects supports the hypothesis that they are free of
airway inflammation. Indeed, eosinopils that are charac-
teristic of asthma are not attracted to the airways upon
provocation with a stimulus that does attract these cells
in patients with persistent asthma, even when similar
doses of AMP are being inhaled.
This study also demonstrates that sputum induction
after AMP provocation gives more information than
sputum induction at baseline alone. After all, the differ-
ences between asthma remission and current asthma
would not have been recognized if only baseline sputum
measurements had been compared, especially since all
asthma patients had stable disease without using inhaled
steroids. We can speculate about the underlying
mechanisms that are responsible for the differences
observed. Apparently the immunological mechanisms
involved in recruiting eosinophils into the airway lumen
differs between subjects with complete asthma remission
and patients with current asthma. It is possible that
immunologically primed mast cells may have disap-
peared in subjects with complete asthma remission.
Thus activation of the adenosine 2b receptor by AMP
might not take place and neither the release of mast cell
mediators. The loss of immunologically primed mast
cells was not reflected by our data on histamine levels
in sputum supernatant, histamine levels being similar in
all groups. Bronchial biopsy studies are needed to
further investigate the role of mast cells in complete
asthma remission.
This study does not completely prove that our sub-
jects with complete asthma remission fully have out-
grown their asthma, as we did not compare results with
healthy controls. Several studies suggest that a cut off
value of 1% for sputum eosinophils can discriminate
between current asthma and healthy controls[17-19]. In
our study, two subjects with complete asthma remission
had > 1% sputum eosinophils, possibly indicating that
asthmatic inflammation may still be present in the air-
ways. However, only one subject in the complete asthma
remission group had a sputum eosinophil percentage >
1% after AMP provocation. To our knowledge, no stu-
dies have investigated AMP induced sputum eosinophils
in healthy controls, which clearly needs further study.
Obviously, biopsy studies comparing subjects with
complete asthma remission and healthy controls are
needed to obtain a definite answer as to whether airway
inflammation has disappeared entirely in subjects with
complete asthma remission. Such studies might validate
sputum induction after AMP provocation as a useful
non-invasive tool to recognize patients who really have
outgrown their asthma. Also longitudinal studies are
needed to investigate if symptoms do not recur in
patients suspected to be in complete asthma remission.
To compare the effects of the high cumulative doses
of AMP on the influx of sputum inflammatory cells, we
divided patients with current asthma in groups with and
without a bronchoconstrictive response to AMP. The
PC20 AMP negative group, that still had a proven
bronchoconstrictive response to histamine, received
exactly the same cumulative dose of AMP as the com-
plete asthma remission group (with negative PC20 hista-
mine). In contrast to subjects with complete asthma
remission, this group of current asthma patients with a
negative PC20 AMP showed a modest but significant
increase in sputum eosinophils after AMP provocation.
This result indicates that AMP has a differential effect
on bronchoconstriction and bronchial inflammation in
asthmatics with proven hyperresponsiveness to
histamine.
An intriguing finding is the discrepancy between the
presence of a positive PC20 histamine and absence of
PC20 AMP in current asthmatics. We realize that the
cut off values of 320 mg for PC20 AMP and 32 mg/ml
for histamine are arbitrary and not objectively based on
the presence or absence of asthmatic airway inflamma-
tion. Nevertheless, it may well be that current asth-
matics with a positive PC20 AMP represent a different
subset of asthma patients. Indeed, significant differences
between the two groups are present in our study.
Despite a lower cumulative dose of AMP, those with
PC20 AMP had significantly more sputum eosinophilia
than those without a PC20 AMP and similar trends were
observed with sputum ECP. In addition, reversibility to
salbutamol and the presence of specific IgE in serum
were significantly higher in the asthma group with a
positive PC20 AMP. A similar association between AMP
sensitivity and atopic status has been described in an
earlier study[20]. It would be of interest to follow the
asthmatics with a negative AMP test to assess whether
they will develop clinical asthma remission. In other
words it might represent an intermediate state between
full blown asthmatic inflammation and absence of
inflammation.
Conclusions
We conclude that our results suggest that the definition
of complete asthma remission is valid, since sputum
eosinophils do not increase after AMP provocation. This
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current asthma that occurs even in the absence of a
bronchoconstrictive response to AMP.
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